Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnovivaINVA -2.23%86 EV-to-EBITDA is 2.60 as of Aug. 21, 2026, which is 60% below its 10-year median of 6.54. GuruFocus rates INVA with a GF Score™ of 86/100 and a GF Value™ of $23.28 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 406 Biotechnology companies, Innoviva ranks better than 73.89% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Innoviva's enterprise value is $1,208.5 Mil.
Innoviva's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $464.1 Mil. Therefore, Innoviva's EV-to-EBITDA for today is 2.60.
The historical rank and industry rank for Innoviva's EV-to-EBITDA or its related term are showing as below:
INVA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.29 Med: 6.54 Max: 2003.72
Current: 2.6
During the past 13 years, the highest EV-to-EBITDA of Innoviva was 2003.72. The lowest was 2.29. And the median was 6.54.
INVA's EV-to-EBITDA is ranked better than 73.89% of 406
companies
in the Biotechnology industry
Industry Median: 14.4
vs INVA: 2.60
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Innoviva's share price for today is $21.01.
Innoviva's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.100.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Innoviva's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innoviva's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innoviva EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innoviva's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Innoviva's EV-to-EBITDA falls into.
Innoviva's current Enterprise Value is $1,208.5 Mil.
Innoviva's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $464.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innoviva (INVA) has a EV-to-EBITDA of 2.60 as of Aug. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Innoviva. This is 60% below median its historical median of 6.54. Over the past decade, Innoviva's EV-to-EBITDA has ranged from 2.29 to 2,003.72. According to the industry distribution chart, Innoviva ranks #106 out of 406 companies in the Biotechnology industry, placing it in the top 26.1%.
Is Innoviva's EV-to-EBITDA too high?
Innoviva's current EV-to-EBITDA of 2.60 is 60% below median its 10-year median of 6.54. Over the past 10 years, this metric has ranged from a low of 2.29 to a high of 2,003.72. The Biotechnology industry median EV-to-EBITDA is 14.40. Innoviva's value of 2.60 is 81.9% below this industry median. Based on the distribution chart, Innoviva ranks #106 out of 406 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Innoviva has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innoviva's EV-to-EBITDA compare to TSHA and MLTX?
According to the Biotechnology industry distribution chart, Innoviva ranks #106 out of 406 companies for EV-to-EBITDA. This puts Innoviva in the upper half of its industry. The industry median EV-to-EBITDA is 14.40. Innoviva's value of 2.60 is 81.9% below this benchmark. Historically, Innoviva's own EV-to-EBITDA has ranged from 2.29 to 2,003.72 over the past decade. While the company's 10-year median is 6.54 vs. the industry median of 14.40, Innoviva has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 14.40, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innoviva's current EV-to-EBITDA of 2.60 is 81.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Innoviva. For the Biotechnology industry, the median EV-to-EBITDA is 14.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innoviva's current EV-to-EBITDA is 2.60, which is 60% below median its own 10-year median of 6.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innoviva stock overvalued right now?
Based on GuruFocus' analysis, Innoviva (INVA) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.28, compared to a current price of $21.01 — trading 9.8% below its estimated fair value. The current EV-to-EBITDA is 2.60, which is 60% below median its 10-year median of 6.54 and 81.9% below the Biotechnology industry median of 14.40. Innoviva's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Innoviva (INVA), the current EV-to-EBITDA is 2.60 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innoviva (INVA) Overvalued in 2026?
Based on GuruFocus' analysis, Innoviva stock appears to be undervalued.
The current stock price of $21.01 is trading 9.8% below its estimated GF Value™ of $23.28.
GuruFocus considers Innoviva to be Modestly Undervalued.
Key valuation signals for INVA:
EV-to-EBITDA: 2.60 (60% below median its 10-year median of 6.54)
GF Value™: $23.28 vs. price of $21.01 (9.8% below fair value)
Industry Position: 81.9% below the Biotechnology median (#106 of 406)
No single metric tells the full story. See the INVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
86GF Score
Get the complete analysis for INVA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INVA has been successfully added to your 
